3005-7590

IJTLD OPEN

International Union Against Tuberculosis and Lung Disease

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add license metadata to 296 records

License metadata tells indexers and readers how each article may be reused.

High impact296 DOIs
2

Attach ORCID iDs across 287 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact287 DOIs
3

Add abstracts to 80 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact80 DOIs

DOIs for this ISSN

Showing the top 5 of 296 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Impact of US funding cuts and stop work orders on TB service… (10.5588/ijtldopen.25.0168)
Abstract ORCID License
108.54 27
2 Global reporting on TB in children and adolescents: how far… (10.5588/ijtldopen.23.0529)
Abstract ORCID License
102.13 22
3 Sputum availability and quality in country-level TB prevalen… (10.5588/ijtldopen.24.0117)
Abstract ORCID License
83.55 12
4 Perspectives from the 2 <sup>nd</sup>… (10.5588/ijtldopen.23.0619)
ORCID License
78.99 37
5 Disability, comorbidities and risk determinants at end of TB… (10.5588/ijtldopen.24.0082)
ORCID License
65.05 19
6 Guidelines for the diagnosis and management of post-TB lung… (10.5588/ijtldopen.24.0093)
Abstract ORCID License
63.38 6
7 Willingness to accept new TB vaccines among adults, adolesce… (10.5588/ijtldopen.25.0177)
Abstract ORCID License
63.38 6
8 Applying ‘timeliness’ to the screening and prevention of TB… (10.5588/ijtldopen.23.0615)
Abstract ORCID License
58.36 5
9 Quantifying sputum production success during community-based… (10.5588/ijtldopen.24.0319)
Abstract ORCID License
58.36 5
10 Rethinking latent TB? Think again (10.5588/ijtldopen.24.0336)
Abstract ORCID License
58.36 5
11 Mapping TB incidence across districts in Uganda to inform he… (10.5588/ijtldopen.23.0624)
ORCID License
55.70 12
12 TB among refugees from Ukraine in European countries (10.5588/ijtldopen.24.0062)
ORCID License
55.70 12
13 Considering best practice standards for routine whole-genome… (10.5588/ijtldopen.24.0320)
ORCID License
55.70 12
14 Updated treatment guidelines for drug-resistant TB: how safe… (10.5588/ijtldopen.24.0490)
ORCID License
55.70 12
15 Post-TB sequelae in adolescent pulmonary TB survivors (10.5588/ijtldopen.24.0039)
ORCID License
53.96 11
16 Prevalence of TB-related symptoms and self-reported disabili… (10.5588/ijtldopen.24.0141)
ORCID License
53.96 11
17 Leveraging Global Fund’s investments to expand innovative pu… (10.5588/ijtldopen.24.0162)
ORCID License
53.96 11
18 Experience of piloting BPaLM/BPaL for DR-TB care at selected… (10.5588/ijtldopen.24.0369)
ORCID License
53.96 11
19 Impact of race-neutral global reference equations on spirome… (10.5588/ijtldopen.24.0224)
Abstract ORCID License
52.42 4
20 2022 TB programme review in Pakistan: strengthening governan… (10.5588/ijtldopen.23.0587)
ORCID License
52.07 10
21 Timing of recurrence after treatment of pulmonary TB (10.5588/ijtldopen.24.0222)
ORCID License
52.07 10
22 Beyond a cure for TB: confronting the hidden burden of post-… (10.5588/ijtldopen.25.0222)
ORCID License
52.07 10
23 Timeliness metrics for screening and preventing TB in househ… (10.5588/ijtldopen.23.0545)
ORCID License
50.00 9
24 Savings from the introduction of BPaL and BPaLM regimens at… (10.5588/ijtldopen.24.0213)
ORCID License
50.00 9
25 Efficacy and safety data on pretomanid for drug-resistant TB (10.5588/ijtldopen.24.0360)
ORCID License
50.00 9
26 Treatment success rate and time to culture conversion under… (10.5588/ijtldopen.24.0524)
ORCID License
47.71 8
27 The Western Pacific Regional Framework to End TB: overview a… (10.5588/ijtldopen.24.0608)
ORCID License
47.71 8
28 Characteristics of TPT initiation and completion among peopl… (10.5588/ijtldopen.23.0194)
ORCID License
45.15 7
29 Psychosocial needs of adolescents living with TB in Peru and… (10.5588/ijtldopen.23.0443)
Abstract ORCID License
45.15 3
30 More is needed to end TB: commentary on the United Nations H… (10.5588/ijtldopen.23.0576)
Abstract ORCID License
45.15 3
31 Launch of <i>IJTLD OPEN</i>… (10.5588/ijtldopen.23.0598)
Abstract ORCID License
45.15 3
32 Management challenges and outcomes for non-tuberculous mycob… (10.5588/ijtldopen.24.0140)
Abstract ORCID License
45.15 3
33 The implementation of whole-genome sequencing for… (10.5588/ijtldopen.24.0147)
Abstract ORCID License
45.15 3
34 Comprehensive care for people affected by TB: addressing TB-… (10.5588/ijtldopen.24.0167)
Abstract ORCID License
45.15 3
35 Antibacterial action of penicillin against… (10.5588/ijtldopen.24.0238)
ORCID License
45.15 7
36 The intersection of TB and health financing: defining needs… (10.5588/ijtldopen.24.0324)
ORCID License
45.15 7
37 Accelerating TB regimen development: introducing FAST-TB (10.5588/ijtldopen.24.0333)
Abstract ORCID License
45.15 3
38 Impact of heteroresistance on treatment outcomes of people w… (10.5588/ijtldopen.24.0343)
ORCID License
45.15 7
39 Perceptions and clinical practices associated with post-TB h… (10.5588/ijtldopen.24.0377)
Abstract ORCID License
45.15 3
40 Disseminated TB associated with acute severe malnutrition in… (10.5588/ijtldopen.24.0454)
Abstract ORCID License
45.15 3
41 Comparative efficacy of tetracyclines against isolates of… (10.5588/ijtldopen.24.0551)
Abstract ORCID License
45.15 3
42 Acceptability of levofloxacin dispersible and non-dispersibl… (10.5588/ijtldopen.23.0462)
ORCID License
42.25 6
43 Commitment, partnerships and operational research: three pri… (10.5588/ijtldopen.23.0470)
ORCID License
42.25 6
44 Chronic obstructive pulmonary disease related to wood smoke… (10.5588/ijtldopen.24.0004)
ORCID License
42.25 6
45 Cost and cost-effectiveness of BPaL regimen used in drug-res… (10.5588/ijtldopen.24.0094)
ORCID License
42.25 6
46 Accuracy of Truenat™ MTB Plus for the diagnosis of pulmonary… (10.5588/ijtldopen.24.0561)
ORCID License
42.25 6
47 15-year trends in efficacy and effectiveness of treatment ou… (10.5588/ijtldopen.24.0620)
ORCID License
42.25 6
48 Urgent request for pretomanid label expansion to align with… (10.5588/ijtldopen.25.0152)
ORCID License
42.25 6
49 Clinical best practices for caring for people with expanded… (10.5588/ijtldopen.25.0240)
ORCID License
42.25 6
50 Screening of household contacts for TB infection in Cote d'I… (10.5588/ijtldopen.23.0342)
ORCID License
38.91 5